[Correspondence] EVEREST and the eosinophil paradox

The most thought-provoking finding in the Evaluating Treatment Responses Of Dupilumab Versus Omalizumab (EVEREST) trial is not dupilumab's superiority, but its eosinophil paradox—transient eosinophil elevation after treatment correlating with significantly better efficacy than omalizumab's sustained suppression.1 This occurrence challenges our traditional understanding of type 2 inflammation, suggesting that eosinophils might participate in tissue repair rather than simply acting as pathogenic mediators.